<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Ferrario, Franco</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Updates in SLE and Scleroderma</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2006</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2006-09-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">25-27</style></pages><abstract><style  face="normal" font="default" size="100%">Systemic lupus erythematosus (SLE) and systemic sclerosis (SSc; scleroderma) are autoimmune disorders that belong to a largergroup of connective tissue diseases that can occur at all ages. SLE (lupus) is a chronic autoimmune disorder that can affect virtually any organ of the body. This article discusses the histopathological criteria for renal lupus and the implications for therapy, neuropsychiatric SLE, the relationship between scleroderma and pulmonary arterial hypertension, as well as future treatments, among other topics.</style></abstract><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">6</style></volume></record></records></xml>